Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Palisade Bio's lead program PALI-2108 will be featured in four presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17-20 in Barcelona. The lineup includes an oral presentation of Phase 1b findings in fibrostenotic Crohn's disease showing early endoscopic improvement and PDE4 target engagement, plus three moderated posters covering gut-targeted exposure, rapid clinical response in ulcerative colitis, and a response-predicting biomarker.
Key figures
- Drug Name
- PALI-2108
- Phase Of Trial
- Phase 1b (presented); advancing into Phase 2
- Conference
- UEG Week 2026, Barcelona, October 17-20, 2026
- Presentation Count
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.